Sanofi (NASDAQ:SNY) Rating Lowered to Buy at StockNews.com

Sanofi (NASDAQ:SNY) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Monday.

Several other research firms have also commented on SNY. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Argus upped their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Trading Down 0.6 %

Shares of NASDAQ:SNY opened at $54.57 on Monday. The firm has a market capitalization of $138.21 billion, a price-to-earnings ratio of 27.42, a price-to-earnings-growth ratio of 1.56 and a beta of 0.60. The business’s 50 day moving average price is $55.95 and its 200-day moving average price is $51.44. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same period in the previous year, the business earned $0.95 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, equities research analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Several large investors have recently bought and sold shares of the business. Dynamic Advisor Solutions LLC grew its holdings in shares of Sanofi by 39.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock worth $2,780,000 after purchasing an additional 16,117 shares during the last quarter. Manning & Napier Advisors LLC purchased a new stake in Sanofi in the second quarter valued at approximately $13,725,000. Mount Yale Investment Advisors LLC boosted its holdings in shares of Sanofi by 44.3% in the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after acquiring an additional 12,806 shares during the period. Jennison Associates LLC increased its holdings in shares of Sanofi by 18.9% in the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock valued at $9,216,000 after acquiring an additional 30,115 shares during the period. Finally, Sei Investments Co. raised its position in Sanofi by 9.3% in the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock valued at $26,926,000 after purchasing an additional 47,297 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.